CYP2U1 is a distinct member of the cytochrome P450 superfamily, enzymes known for their critical role in the metabolism of a wide array of substrates, including xenobiotic and endogenous compounds. The CYP2U1 enzyme is characterized by its specificity for hydroxylating fatty acids, particularly long-chain fatty acids, which underscores its unique position in metabolic processes. Its expression is noted across several tissues, with significant levels in the brain, thymus, and heart, suggesting a specialized function in the metabolism within these organs. The regulation of CYP2U1 expression is a complex interplay of genetic and environmental factors, which ensures that its activity is modulated in response to the body's metabolic demands. Understanding the elements that influence the expression of CYP2U1 is crucial, as they shed light on the broader regulatory networks that govern the metabolism of lipids and other important biological molecules.
A variety of chemical compounds have been identified as activators that could induce the expression of the CYP2U1 protein. These activators typically exert their effects through the activation of specific nuclear receptors or signaling pathways, which then lead to an increase in the transcription and subsequent expression of the CYP2U1 enzyme. For instance, certain agents that act as ligands for nuclear receptors such as the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR) can prompt the upregulation of CYP2U1. Similarly, natural compounds or dietary elements that engage PPAR receptors, which play a pivotal role in lipid metabolism, may also induce the expression of this enzyme. Moreover, environmental factors, such as exposure to particular organic pollutants that activate the aryl hydrocarbon receptor (AhR), are known to stimulate the expression of various cytochrome P450 enzymes, including CYP2U1. These chemical activators are essential in understanding the adaptive responses of the body to a changing metabolic landscape, providing insights into the regulation of CYP2U1 and its role in maintaining physiological homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Rifampicin is known to strongly stimulate P450 enzymes by activating the PXR, which might extend to an increase in CYP2U1 expression. | ||||||
Carbamazepine | 298-46-4 | sc-202518 sc-202518A | 1 g 5 g | $33.00 $71.00 | 5 | |
Carbamazepine may upregulate CYP2U1 through activation of both PXR and CAR, leading to enhanced transcription of various P450 enzymes. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Omeprazole could stimulate the hepatic expression of CYP2U1 by activating the nuclear receptor CAR, which responds to chemical stimuli. | ||||||
Clofibrate | 637-07-0 | sc-200721 | 1 g | $33.00 | ||
Clofibrate is known to upregulate P450 enzymes through activation of PPARs, which may include the transcriptional activation of CYP2U1. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone can stimulate the expression of CYP2U1 by engaging glucocorticoid receptors, which can enhance the transcription of detoxifying enzymes. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone, through its action as a PPARγ agonist, could upregulate the transcription of CYP2U1, enhancing its enzymatic activity related to fatty acid metabolism. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone may stimulate the expression of CYP2U1 through PPARγ-dependent pathways, influencing lipid processing enzymes. | ||||||